Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials

BACKGROUND: Patients with recurrent Clostridium difficile infection (rCDI) are more likely to have a hospital readmission and spend increased time in inpatient settings compared with patients with primary CDI. MODIFY I and II demonstrated that bezlotoxumab significantly reduced rCDI vs placebo. A po...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, Anirban, Prabhu, Vimalanand S, Dorr, Mary Beth, Golan, Yoav, Dubberke, Erik R, Cornely, Oliver A, Heimann, Sebastian M, Pedley, Alison, Xu, Ruifeng, Hanson, Mary E, Marcella, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237242/
https://www.ncbi.nlm.nih.gov/pubmed/30460321
http://dx.doi.org/10.1093/ofid/ofy218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237242/
https://www.ncbi.nlm.nih.gov/pubmed/30460321
http://dx.doi.org/10.1093/ofid/ofy218

Ejemplares similares